Implanet Launches JAZZ Evo to Treat Adult Degenerative Spine Disease

Implanet, a medical technology company specializing in vertebral and knee-surgery implants, has launched JAZZ Evo, a new evolution of the JAZZ implant developed to respond to the constraints of vertebral fusion indications in adults.
 
Developed primarily to facilitate the treatment of degenerative pathologies in adults, JAZZ Evo is the first implant in a new range of JAZZ connectors to be launched at a steady rate over the next two years. The implant benefits from the intellectual property protection of the JAZZ range, a system for blocking the braid with a single screw, ensuring optimum clamping on the rod without damaging the braid. JAZZ Evo is available in three diameters representing 90 percent of diameters used in degenerative spine surgery and can be used with the JAZZ Passer Band, the braid specially designed for use in adults. Jazz Evo has already obtained CE marking and U.S. Food and Drug Administration 510(k) clearance.
 
Régis Le Couedic, R&D director at Implanet, commented: “With the aim of permanent innovation, we work in close collaboration with surgeons to develop our range and optimize the design of the JAZZ implant in order to make it even easier to use. JAZZ Evo embodies Implanet’s approach of targeting the market of degenerative disease in adults. Surgeons are often concerned about the invasive aspect of implants and the reduced size of JAZZ Evo means that its use makes surgery less invasive while also reducing the volume of metal implanted. Like all of our range, JAZZ Evo is a snap-on, auto-stable implant, which makes it easier to position. These features are protected by existing patents.”
 
CEO Ludovic Lastennet added, “JAZZ Evo responds to the issues facing surgeons and patients as well as budgetary concerns, which should allow us to benefit from a major competitive advantage. It is with this in mind that JAZZ Evo has been designed. As previously announced, we are maintaining our pace of innovation with the launch of one product per quarter in order to keep up with our more rapid growth in the U.S., French, German and U.K. markets, which we now target directly. Having demonstrated the medical value of JAZZ in pediatric deformity, with JAZZ Evo we have started to roll out our JAZZ technology in the promising market of degenerative spine disease in adults. This implant represents the first link in a range of JAZZ connectors dedicated exclusively to degenerative spine surgery in adults, a market worth $2.5 billion, four to five times the size of the deformity market.”¹
 
Founded in 2007, Implanet manufactures implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Implanet employs 46 staff and recorded 2017 sales of 7.8 million euros. Based near Bordeaux in France, the company established a U.S. subsidiary in Boston, Mass., in 2013.
 
Reference
1. sources i-Data 2010; D. K. Chin and al. Osteoporos Int (2007) 18:1219–1224.; Company